Healthcare Professionals

• What Makes STAVZOR Unique
  • Request Samples
  • Patient and Caregiver Materials
  • Full Prescribing Information
• Patient Preference Study
• STAVZOR for Bipolar Disorder
  • Dosing Information For Bipolar Disorder
• STAVZOR for Epilepsy
  • Dosing Information For Epilepsy
• STAVZOR for Migraines
  • Dosing Information For Migraines
• Educational Resources

STAVZOR for bipolar disorder

STAVZOR is indicated for the treatment of manic episodes associated with bipolar disorder.

Valproate, the active ingredient in STAVZOR, is recommended as a first-line therapy by the American Psychiatric Association.

• Dosing for bipolar disorder
• STAVZOR Prescribing Information

Proven safety profile of valproate

Valproate has low rate of discontinuation due to intolerance in bipolar disorder. In two clinical trials, the rate of drug discontinuation due to intolerance was not statistically different among placebo (4%), valproate (8%) and lithium (11%).

In adjunctive therapy, as the STAVZOR dosage is titrated upward, concentrations of clonazepam, diazepam, ethosuximide, lamotrigine, tolbutamide, phenobarbital, carbamazepine, and/or phenytoin may be affected.
In converting to monotherapy, reduce concomitant antiepileptic drug (AED) by ~25% every 2 weeks. The speed and duration of withdrawal can be highly variable, and patients should be monitored closely. Reduction of concomitant AED can start at initiation of STAVZOR, or 1 to 2 weeks later if concerned that seizures may occur with reduction.